How Recursion is leading a new era of AI-driven drug discovery AI drug discovery is not a new phenomenon – but it is evolving at an almost dizzying pace. Recursion is one of the earliest innovators in ...

In early December 2025, Recursion Pharmaceuticals released clinical data from the TUPELO Phase 1b/2 trial of REC-4881, providing fresh insight into the candidate’s safety and efficacy profile. This ...

Dec 8 (Reuters) - Recursion Pharma (RXRX.O), opens new tab, which uses artificial intelligence to discover new drug candidates, said on Monday its experimental oral drug helped reduce abnormal growths ...

Three Harvard faculty said they think fears that an artificial intelligence bubble will burst — leading stock prices to collapse in the wake of soaring investments into AI companies — are overblown ...

OpenAI CEO Sam Altman's comments helped spark concerns about an AI bubble. Mark Cuban says he doesn't see similarities to the dot-com bubble. There's disagreement, even among business leaders and tech ...

Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology and chemistry by integrating technological innovations across biology, chemistry, ...

“We’re in the phase of the cycle where the rubber meets the road,” said Jim Morrow, chief executive officer of Callodine Capital Management. “It’s been a good story, but we’re sort of anteing up at ...